Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study

被引：0
|
作者：
机构：
[1] Lancet Oncol, 125 London Wall, London EC2Y 5AS, England
来源：
LANCET ONCOLOGY | 2023年 / 24卷 / 04期
关键词：
D O I：
10.1016/S1470-2045(23)00111-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E145 / E145
页数：1
相关论文
共 50 条
  • [1] RETRACTED: Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL) : a multicentre, open-label, single-arm, phase 2 study (Retracted Article)
    Dummer, Reinhard
    Queirolo, Paola
    Guijarro, Ana Maria Abajo
    Hu, Youyou
    Wang, Dao
    de Azevedo, Sergio Jobim
    Robert, Caroline
    Ascierto, Paolo Antonio
    Chiarion-Sileni, Vanna
    Pronzato, Paolo
    Spagnolo, Francesco
    Eizmendi, Karmele Mujika
    Liszkay, Gabriella
    Merino, Luis de la Cruz
    Tawbi, Hussein
    LANCET ONCOLOGY, 2022, 23 (09): : 1145 - 1155
  • [2] Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study
    McArthur, G. A.
    Maio, M.
    Arance, A.
    Nathan, P.
    Blank, C.
    Avril, M. -F.
    Garbe, C.
    Hauschild, A.
    Schadendorf, D.
    Hamid, O.
    Fluck, M.
    Thebeau, M.
    Schachter, J.
    Kefford, R.
    Chamberlain, M.
    Makrutzki, M.
    Robson, S.
    Gonzalez, R.
    Margolin, K.
    ANNALS OF ONCOLOGY, 2017, 28 (03) : 634 - 641
  • [3] A single-arm, open-label, US expanded access study of vemurafenib in patients with metastatic melanoma.
    Schuchter, Lynn Mara
    Flaherty, Lawrence E.
    Hamid, Omid
    Linette, Gerald P.
    Hallmeyer, Sigrun
    Gonzalez, Rene
    Cowey, Charles Lance
    Pavlick, Anna C.
    Kudrik, Fred J.
    Lawson, David H.
    Margolin, Kim Allyson
    Ribas, Antoni
    McDermott, David F.
    Khatcheressian, James L.
    Flaherty, Keith T.
    Day, Bann-Mo
    Linke, Rolf Gerhard
    Hainsworth, John D.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [4] A Single-Arm, Open-Label, Expanded Access Study of Vemurafenib in Patients With Metastatic Melanoma in the United States
    Flaherty, Lawrence
    Hamid, Omid
    Linette, Gerald
    Schuchter, Lynn
    Hallmeyer, Sigrun
    Gonzalez, Rene
    Cowey, C. Lance
    Pavlick, Anna
    Kudrik, Fred
    Curti, Brendan
    Lawson, David
    Chapman, Paul B.
    Margolin, Kim
    Ribas, Antoni
    McDermott, David
    Flaherty, Keith
    Cranmer, Lee
    Hodi, F. Stephen
    Day, Bann-Mo
    Linke, Rolf
    Hainsworth, John
    CANCER JOURNAL, 2014, 20 (01): : 18 - 24
  • [5] Atezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: A multicenter, open-label, single-arm phase 2 study.
    Mao, Lili
    Fang, Meiyu
    Chen, Yu
    Bai, Xue
    Cao, Jun
    Lin, Jing
    Zhang, Peng
    Chen, Ling
    Xu, Jiahui
    Guo, Jun
    Si, Lu
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [6] Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study
    Mao, Lili
    Fang, Meiyu
    Chen, Yu
    Wei, Xiaoting
    Cao, Jun
    Lin, Jing
    Zhang, Peng
    Chen, Ling
    Cao, Xiao
    Chen, Yujun
    Guo, Jun
    Si, Lu
    CLINICAL CANCER RESEARCH, 2022, 28 (21) : 4642 - 4648
  • [7] AN OPEN-LABEL, MULTICENTRE SAFETY STUDY OF VEMURAFENIB IN PATIENTS WITH METASTATIC MELANOMA
    Blank, C.
    Del Vecchio, M.
    Ascierto, P. A.
    Queirolo, P.
    Hauschild, A.
    Arance, A.
    Brown, M.
    Mitchell, L.
    Veronese, L.
    Larkin, J.
    ANNALS OF ONCOLOGY, 2012, 23 : 366 - 366
  • [8] Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study
    Namikawa, Kenjiro
    Kiyohara, Yoshio
    Takenouchi, Tatsuya
    Uhara, Hisashi
    Uchi, Hiroshi
    Yoshikawa, Shusuke
    Takatsuka, Sumiko
    Koga, Hiroshi
    Wada, Naoko
    Minami, Hironobu
    Hatsumichi, Masahiro
    Asada, Suguru
    Namba, Yoshinobu
    Yamazaki, Naoya
    EUROPEAN JOURNAL OF CANCER, 2018, 105 : 114 - 126
  • [9] Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial
    Shu, Catherine A.
    Gainor, Justin F.
    Awad, Mark M.
    Chiuzan, Codruta
    Grigg, Claud M.
    Pabani, Aliyah
    Garofano, Robert F.
    Stoopler, Mark B.
    Cheng, Simon K.
    White, Abby
    Lanuti, Michael
    D'Ovidio, Frank
    Bacchetta, Matthew
    Sonett, Joshua R.
    Saqi, Anjali
    Rizvi, Naiyer A.
    LANCET ONCOLOGY, 2020, 21 (06): : 786 - 795
  • [10] Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial
    Morschhauser, Franck
    Tilly, Herve
    Chaidos, Aristeidis
    McKay, Pamela
    Phillips, Tycel
    Assouline, Sarit
    Batievi, Connie Lee
    Campbell, Phillip
    Ribrag, Vincent
    Damaj, Gandhi Laurent
    Dickinson, Michael
    Jurczak, Wojciech
    Kazmierczak, Maciej
    Opat, Stephen
    Radford, John
    Schmitt, Anna
    Yang, Jay
    Whalen, Jennifer
    Agarwal, Shefali
    Adib, Deyaa
    Salles, Gilles
    LANCET ONCOLOGY, 2020, 21 (11): : 1433 - 1442
12345